Methylprednisolone Adjunctive to Endovascular Treatment for Stroke - Trial NCT06360458
Access comprehensive clinical trial information for NCT06360458 through Pure Global AI's free database. This Phase 3 trial is sponsored by Wan-Jin Chen and is currently Not yet recruiting. The study focuses on Acute Ischemic Stroke. Target enrollment is 735 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Wan-Jin Chen
First Affiliated Hospital of Fujian Medical University
Timeline & Enrollment
Phase 3
May 01, 2024
Mar 01, 2028
Primary Outcome
Mortality at 90 days
Summary
The efficacy and safety of methylprednisolone in acute ischemic stroke patients with large
 infarct cores (ASPECTS score 6) due to anterior circulation large vessel occlusion have not
 been clearly established. This is a multi-center, randomized, double-blind,
 placebo-controlled trial to investigate early combination therapy with methylprednisolone for
 reperfusion in acute large core infarction.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06360458
Non-Device Trial